scPharmaceuticals Inc. reported net FUROSCIX revenue of $16.0 million for the second quarter of 2025, marking a 99% increase over Q2 2024. Doses shipped to patients also saw substantial growth, increasing 45% over Q1 2025 and 117% over Q2 2024, reflecting strong execution and increasing prescriber adoption.
The company's net loss for the second quarter was $18.0 million, compared to $17.1 million in Q2 2024. Research and development expenses increased to $4.1 million, primarily due to device development and pharmaceutical development costs. Cash and cash equivalents stood at $40.8 million as of June 30, 2025.
scPharmaceuticals highlighted the successful launch of FUROSCIX in the chronic kidney disease (CKD) market as a critical step in transforming diuretic therapy. Management also noted the proposed Ambulatory Specialty Model (ASM) by CMS on July 14, 2025, as a potential tailwind, as it aims to improve heart failure management by linking Medicare Part B payments to specialists' performance in reducing unplanned hospitalizations. The Autoinjector remains on track for sNDA submission in Q3 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.